Pernix Therapeutics (PTX) Reports Q3 Loss of $2.99/Share

Pernix Therapeutics (NASDAQ: PTX) reported Q3 EPS of ($2.99), versus ($1.76) reported last year. Revenue for the quarter came in at $41.5 million, versus $48.6 million reported last year.

For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• PMI and Altria strike cigarette contract manufacturing deal
• Scinai posts H1 2026 results with wider operating loss, net gain